The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.
The great news for investors is that there are many strong contenders for the best stock to buy, with the Fed cutting interest rates. Lower rates help nearly every company. However, some sectors ...